Current status of HIV therapy: II. Opportunistic diseases.
Infections and malignancies account for most deaths in patients with AIDS--and will continue to do so as long as HIV-induced immunosuppression is progressive and irreversible. Options available for prevention and improved management of such diseases are changing as new agents emerge, new combinations of agents are developed, and new indications for available agents are identified.
Feinberg
J
J
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.
Hoth
D F
DF
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000401:mortality; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015774:Ganciclovir / Q000627:therapeutic use; D006660:Histoplasmosis / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D009894:Opportunistic Infections / Q000150:complications* / Q000188:drug therapy / Q000517:prevention & control; D010419:Pentamidine / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000150:complications* / Q000517:prevention & control; D012514:Sarcoma, Kaposi / Q000150:complications* / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D010419:Pentamidine; D015774:Ganciclovir